PO.BCS01.16 · 生物信息与计算
TP53突变型胶质瘤中分级依赖的生存和共突变图景：生物学见解与治疗意义
Grade-dependent survival and co-mutation landscapes in TP53-mutant gliomas: Biological insights and therapeutic implications
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景：胶质瘤在各分级间表现出广泛的异质性，从较低级别的间变性肿瘤（2级和3级）到胶质母细胞瘤（GBM，4级）不等。TP53突变频繁发生，但其预后意义在很大程度上取决于共突变情境和肿瘤分级。剖析这些相互作用对于分层和治疗至关重要。
方法：我们分析了来自癌症基因组图谱（TCGA）和纪念斯隆凯特琳（MSKCC）队列的体细胞突变和生存数据，数据来自TCGAbiolinks和cBioPortal。突变分析和共突变网络分析使用maftools进行，Kaplan-Meier和Cox回归模型评估了分级和情境特异性的生存效应。治疗相关性从OncoKB和NCI-MATCH中整理。
结果：在2级胶质瘤中，TP53突变型肿瘤表现出显著的生存优势（40.2个月对比野生型的19.4个月），并富集IDH1和ATRX共突变。3级TP53突变型肿瘤保留了这一优势（32.9个月对比15.2个月），并伴有MUC16和APOB的额外突变。相比之下，GBM（4级）仅表现出适度的TP53获益（14.8个月对比11.5个月），因为保护性的IDH1/ATRX共突变罕见，而增殖驱动因素（EGFR、PTEN、NF1、PI3K）占主导。在TP53突变型胶质瘤内部，生存因共突变谱而分化。有利突变（ATRX、IDH1、COL6A3、LAMA1、HYDIN、ADGRV1、NAV2）与较缓慢的生长、免疫可见性或较低级别生物学特征相关。突变（PTEN、EGFR、RB1、NF1）产生适度影响。相比之下，有害共突变（OBSCN、PRDM9、DNAH11、PTPN3）放大了基因组不稳定性，定义了预后最差的亚组。
结论：TP53在胶质瘤中的预后作用由分级特异性共突变情境所塑造。伴有IDH1/ATRX的TP53突变型肿瘤类似于较低级别胶质瘤，可能从IDH抑制剂中获益，而伴有增殖或不稳定性驱动因素的肿瘤可能需要PI3K/mTOR抑制或临床试验入组。这一整合框架凸显了在预后判断和治疗决策中进行共突变感知分层的必要性。
查看英文原文 English abstract
Background: Gliomas display wide heterogeneity across grades, ranging from lower-grade anaplastic tumors (grades 2 and 3) to glioblastoma (GBM, grade 4). TP53 mutations occur frequently, but their prognostic significance depends strongly on co-mutation context and tumor grade. Dissecting these interactions is critical for stratification and therapy.
Methods: We analyzed somatic mutation and survival data from The Cancer Genome Atlas (TCGA) and Memorial Sloan Kettering (MSKCC) cohorts from TCGAbiolinks, and cBioPortal. Mutational profiling and co-mutation network analyses were performed using maftools, Kaplan-Meier and Cox regression models evaluated grade- and context-specific survival effects. Therapeutic associations were curated from OncoKB and NCI-MATCH.
Results: In grade 2 gliomas, TP53-mutant tumors showed a major survival advantage (40.2 vs 19.4 months in WT), enriched for co-mutations in IDH1 and ATRX. Grade-3 TP53-mutant tumors retained this advantage (32.9 vs 15.2 months) with additional mutations in MUC16 and APOB. By contrast, GBM (grade 4) showed only a modest TP53 benefit (14.8 vs 11.5 months), as protective IDH1/ATRX co-mutations were rare and proliferative drivers (EGFR, PTEN, NF1, PI3K) dominated. Within TP53-mutant gliomas, survival diverged by co-mutation profile. Favorable mutations (ATRX, IDH1, COL6A3, LAMA1, HYDIN, ADGRV1, NAV2) were linked to slower growth, immune visibility, or lower-grade biology. Mutations (PTEN, EGFR, RB1, NF1) exerted modest effects. In contrast, deleterious co-mutations (OBSCN, PRDM9, DNAH11, PTPN3) amplified genomic instability, defining a worst-prognosis subgroup.
Conclusions: The prognostic role of TP53 in gliomas is shaped by grade-specific co-mutation context. TP53-mutant tumors with IDH1/ATRX resemble lower-grade gliomas and may benefit from IDH inhibitors, whereas tumors with proliferative or instability drivers may require PI3K/mTOR inhibition or trial enrollment. This integrative framework highlights the need for co-mutation-aware stratification in both prognostication and therapeutic decision-making.
利益披露 Disclosure
H. Kaur, None..
K. Camphausen, None..
U. Shankavaram, None.